BEIJING, Nov. 30, 2023 /PRNewswire/ — Weibo Corporation ("Weibo" or the "Company") (Nasdaq: WB; HKEX: 9898), a leading social media in China, today announced the commencement of the offering of American Depositary Shares ("ADSs"), each currently representing one Class A ordinary share of Weibo, par value US$0.00025 per share (the "ADS Offering"), which the Company intends to loan (such loaned ADSs, the "Borrowed ADSs") to an affiliate of the underwriter in the ADS Offering (such affiliate, the "ADS Borrower") pursuant to an ADS lending agreement with the ADS Borrower (the "ADS Lending Agreement").

Concurrently with the ADS Offering, the Company announced the offering (the "Notes Offering") of convertible senior notes in an aggregate principal amount of US$300 million due 2030 (the "Notes") pursuant to Rule 144A of the Securities Act of 1933, as amended. The Company intends to grant the initial purchaser in the Notes Offering an option, exercisable within a 30-day period, beginning on and including the date of the Notes Offering, to purchase up to an additional US$30 million in principal amount of the Notes.

Concurrently with the Notes Offering, the ADS Borrower will sell the Borrowed ADSs in a separate offering registered with the U.S. Securities and Exchange Commission (the "SEC") offered by the underwriter pursuant to a prospectus supplement and an accompanying base prospectus, as described below (the "Delta Placement of Borrowed ADSs"). The number of Borrowed ADSs will be determined at the time of pricing of the Delta Placement of Borrowed ADSs. The Delta Placement of Borrowed ADSs is intended to facilitate short sales and/or privately negotiated derivative transactions by which some investors in the Notes may hedge their exposure to the Notes.

The ADS Borrower or its affiliate will receive all of the proceeds from the sale of the Borrowed ADSs. The Company will not receive any proceeds from the ADSs Offering but will receive from the ADS Borrower a nominal lending fee, which will be applied to fully pay up the Class A ordinary shares underlying the Borrowed ADSs. The Company believes that the Borrowed ADSs will not be considered outstanding for the purpose of computing and reporting its earnings per ADS under the current U.S. Generally Accepted Accounting Principles and, therefore, the Company believes that no dilution will occur as a result of the Borrowed ADSs.

The Delta Placement of Borrowed ADSs is conditioned on the closing of the Notes Offering. If the Notes Offering is not consummated, the ADS Lending Agreement will terminate, the Delta Placement of Borrowed ADSs will terminate and all Borrowed ADSs (or ADSs fungible with Borrowed ADSs) must be returned to the Company.

The Company has filed an automatic shelf registration statement on Form F-3 with the SEC. A prospectus supplement and the related base prospectus describing the terms of the ADS Offering have been filed with the SEC. When available, the final prospectus supplement for the ADS Offering will be filed with the SEC. The ADS Offering is being made only by means of the prospectus supplement and accompanying base prospectus. Before you invest, you should read the prospectus supplement and the accompanying base prospectus and other documents that the Company has filed with the SEC for more complete information about the Company and the offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus may be obtained by contacting Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities, nor shall there be a sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

This press release contains information about the pending offerings of the Notes and the ADSs, and there can be no assurance that any of the offerings will be completed.

About Weibo

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a "mobile first" philosophy, Weibo displays content in a simple information feed format and offers native advertisements that conform to the information feed on its platform. To support the mobile format, Weibo has developed and is continuously refining its social interest graph recommendation engine, which enables its customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Weibo may also make forward-looking statements in the Company’s periodic reports to the SEC, in its interim and annual reports to shareholders, in announcements, circulars or other publications made on the website of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange"), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. These forward-looking statements can be identified by terminology, such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "confidence," "estimates," "likely to" and similar statements. Forward-looking statements involve inherent risks and uncertainties. Among other things, the terms of the Notes, whether the Company will complete the Notes Offering and a description of various hedging activities contain forward-looking statements. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, Weibo’s limited operating history in certain new businesses; failure to grow active user base and the level of user engagement; the uncertain regulatory landscape in China; fluctuations in the Company’s quarterly operating results; the Company’s reliance on advertising and marketing sales for a majority of its revenues; failure to successfully develop, introduce, drive adoption of or monetize new features and products; failure to compete effectively for advertising and marketing spending; failure to successfully integrate acquired businesses; risks associated with the Company’s investments, including equity pick-up and impairment; failure to compete successfully against new entrants and established industry competitors; changes in the macro-economic environment, including the depreciation of the Renminbi; and adverse changes in economic and political policies of the PRC government and its impact on the Chinese economy. Further information regarding these and other risks is included in Weibo’s annual report on Form 20-Fs and other filings with the SEC and the Hong Kong Stock Exchange. All information provided in this press release is current as of the date hereof, and Weibo assumes no obligation to update such information, except as required under applicable law.

Contacts

Investors Relations
Weibo Corporation
Tel: +86-10-5898-3336
Email: [email protected] 

Source : Weibo Corporation Announces Proposed Offering of American Depositary Shares in connection with the Delta Placement of Borrowed ADSs

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

DAEJEON, South Korea, Nov. 29, 2023 /PRNewswire/ — On the 13th of last month, Twinny (CEO Cheon Hong-seok and Cheon Young-seok) announced that it has entered into a strategic business agreement with Hankook Engineering Works (CEO Moon Dong-hwan) to advance the development of autonomous robots. The agreement was made at the headquarters in Daejeon.

Twinny Co-CEOs Cheon Hong-seok and Cheon Young-seok, along with Hankook Engineering Works CEO Moon Dong-hwan, commemorate the signing of a business agreement at Twinny’s Daejeon headquarters on the 13th, as they advance efforts to expand the autonomous robot development business.

Both companies will collaborate on the joint development of autonomous robots. To facilitate smooth product supply, Hankook Engineering Works plans to establish a mass production system. Additionally, the two companies plan to cooperate on the expansion of channels, including factories, logistics centers, and other facilities, both domestically and internationally. They also aim to explore new markets in the logistics sector, such as government offices, train stations, terminals, and mixed-use facilities, utilizing autonomous driving robots.

Cheon Hong-seok, CEO of Twinny, stated, "Through collaboration with Hankook Engineering Works, we will develop and supply logistics transportation robots that combine Twinny’s strengths in autonomous driving technology." He added, "Beyond development, through active cooperation in mass production and business, we will significantly increase market awareness and product supply."

Moon Dong-hwan, CEO of Hankook Engineering Works, mentioned, "Hankook Engineering Works possesses capabilities and networks accumulated over decades as a specialized company in manufacturing facilities for various industries, focusing on automation and unmanned systems." He continued, "As a result of this agreement, both companies will spare no effort in finding the sites where robots are needed and making wholehearted efforts towards customerization to expand the autonomous robot business they aim for."

Founded in 2015 by twin brothers Cheon Hong-seok and Cheon Young-seok, Twinny is a specialized robot company that develops autonomous logistics transportation robots. The company has been at the forefront of developing products that enable autonomous driving indoors and outdoors for purposes such as factory automation and logistics center order picking. Recently, Twinny collaborated with the Korea Railroad to develop and deploy autonomous driving robots at Gwangmyeong Station to enhance the convenience of passengers.

Source : Twinny and Hankook Engineering Works Join Hands to Expand Autonomous Robot Development Business

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING, Nov. 29, 2023 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it developed an integrated multidisciplinary algorithm for clustering heterogeneous datasets, namely, MultiFeatureEvoCluster technology, which not only effectively handles multi-featured datasets, but also assigns explicit semantic meanings to the clustering results.

Traditional clustering methods are based only on attributes, distances, and density values of homogeneous and single-feature datasets, which cannot add clear semantic meaning to the clustering results. WiMi’s MultiFeatureEvoCluster technology is an innovative cluster analysis method designed for processing heterogeneous datasets. The technology integrates advanced techniques and methods from multiple subject areas to ensure efficient processing and accurate clustering of complex datasets.

MultiFeatureEvoCluster employs a recombination evolutionary operator, which is capable of dynamically adjusting the cluster structure of the data during the clustering process, thus improving the adaptability of the clustering algorithm. Second, the technology utilizes Levy on-the-fly optimization, a stochastic search-based optimization method that helps the algorithm quickly find key patterns and clustering features in the data set, accelerating the speed and accuracy of the clustering analysis. In addition, the MultiFeatureEvoCluster incorporates several statistical techniques, including quartiles and percentiles. These can help the algorithm better understand the distribution characteristics and trends of the data, thus improving the accuracy and reliability of the clustering analysis. It also employs the Euclidean distance of the K-mean algorithm as a measure of similarity between data to ensure the validity and stability of the clustering results.

At the core of WiMi’s MultiFeatureEvoCluster technology is a multidisciplinary integration that combines knowledge and techniques from different subject areas to form a unique framework for cluster analysis. By integrating evolutionary algorithms, optimization methods and statistical techniques, MultiFeatureEvoCluster technology can handle complex heterogeneous datasets with different types of data, including text, images, numerical values, etc., and provide users with comprehensive and interpretable cluster analysis results.

The design concept of the technology is to ensure the efficiency and accuracy of the algorithm while making the clustering results have clear semantic meanings. It helps users better understand patterns and associations in data, provides deeper data insights to enterprises and research organizations, and provides powerful support for their decision-making and strategic planning.

Behind the development of MultiFeatureEvoCluster is a multidisciplinary team focused on data analysis and algorithmic innovation, consisting of data experts, statistical specialists and computer scientists. The technology is considered a major advancement over traditional clustering methods, as it breaks through the limitations of single-feature datasets and is capable of handling more complex and diverse data types.

In addition to excelling in clustering accuracy, the MultiFeatureEvoCluster technology demonstrates sensitivity to cluster overlap, number of clusters, cluster dimensionality, cluster structure, and cluster shape. The analysis of these features provides organizations with more dimensional insights into their data, helping them better understand the underlying patterns and trends behind the data. This ability to synthesize and analyze provides a more diversified reference basis for business decision-making, helping companies maintain an edge in a competitive market environment.

Facing the data challenges of the digital era, WiMi has introduced MultiFeatureEvoCluster technology that brings new opportunities and possibilities to enterprises. Its unique multi-feature analysis and evolutionary clustering capabilities make it a rising star in the current data analytics space. For organizations that are eager to mine more value from behind complex data, MultiFeatureEvoCluster technology will surely be a strong partner to help them move towards a data-driven future.

About WIMI Hologram Cloud

WIMI Hologram Cloud, Inc. (NASDAQ:WIMI) is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication and other holographic AR technologies.

Safe Harbor Statements

This press release contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company’s strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission ("SEC") on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company’s expectations regarding demand for and market acceptance of its products and services.

Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement except as required under applicable laws.

Source : WiMi Developed An Integrated Multidisciplinary Algorithm—–MultiFeatureEvoCluster

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HAIKOU, China, Nov. 29, 2023 /PRNewswire/ — China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.

This device has a utility model patent; Epidemiological research shows that the incidence rate of DED for all the  people in China is about 25% to 30%, and about 75% for people over 65-year-old; In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.

Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company’s cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company’s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations, except as required by applicable law or regulation.

Source : China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ — Wondershare Edraw, a prominent market leader in the field of mind mapping and diagramming tools, is excited to announce substantial user experience enhancements for both EdrawMax and EdrawMind.

The recent transformation of EdrawMax to V13 brings a new user interface and an extensive collection of over 26,000 vector graphics, along with intelligent AI diagram tools. EdrawMax enables users to create charts and diagrams with improved productivity and a better overall experience.

EdrawMind V11, an advanced mind mapping tool, introduces an industry-first cross-platform integration, allowing users to collaborate seamlessly across multiple devices. This update revolutionizes the collaborative landscape by offering enhanced multi-user functionality and cloud file management. EdrawMind is dedicated to optimizing teamwork, boosting collaboration efficiency, and empowering users with a versatile and dynamic collaborative environment.

Kim, Head of Product for Wondershare Edraw, states, "EdrawMax V13 and EdrawMind V11 embody our commitment to user-centric innovation. The refreshed UI and UX of EdrawMax reflect our dedication to user experience, while the multi-platform integration of EdrawMind redefines collaborative possibilities. We believe these updates will empower our users to achieve more, collaborate seamlessly, and visualize their ideas with greater ease."

With these enhancements, Wondershare Edraw continues its mission to make complex ideas simple and enable users worldwide to unleash their full creative potential.

Compatibility and Price

Wondershare EdrawMax and EdrawMind are compatible with Windows, Mac, Android, and iOS. EdrawMax pricing starts at $69 for a six-month subscription, and EdrawMind pricing starts at $39 for a six-month subscription. For free trials and downloads, please visit our official website or follow us on YouTube, Facebook, Twitter, and Instagram.  

About Wondershare:

Wondershare Technology is a global leader in software development and a pioneer in the field of digital creativity and productivity solutions. Celebrated for its commitment to innovation, Wondershare has earned accolades from The Shorty Awards, G2, and GetApp, distinguishing itself in the tech community. Serving over 100 million users in 150 countries, Wondershare provides a vast portfolio of applications that enhance video editing, PDF editing, and data recovery.

Source : Wondershare Edraw Empowers Users with Major Upgrades for EdrawMax and EdrawMind

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

ABU DHABI, United Arab Emirates, Nov. 30, 2023 /PRNewswire/ — Building upon the successes of MENA’s biggest Fintech Festival presented by Abu Dhabi Global Market (ADGM), the 7th edition of Fintech Abu Dhabi welcomed an impressive turnout of financial tech leaders and visionaries converging from across the globe today. This included those leading innovation in major financial institutions, startups, innovators, entrepreneurs, venture capitalists, scientists and academics, solidifying Abu Dhabi’s position as a forward-thinking innovation and tech hub.

ADGM’s flagship event, Fintech Abu Dhabi, conducted in partnership with Huawei continued to be a highlight of Abu Dhabi Finance Week (ADFW) this year, focusing on the central theme of the event – ‘The Convergence of Finance and Technology’. The event kicked off with a lively debate on the financial crime economy and brought together prominent AI institutions in Abu Dhabi to discuss the city’s early commitment to AI. Participants also delved into the maturity of the crypto industry. Dr. Alexander Lipton, Global Head of Research & Development at ADIA provided insights on how social media is reshaping the global banking landscape, while the CEO of Circle outlined strategies for harnessing digital assets to enhance global financial stability. Other interesting sessions today included ‘Decoding a "Skandal" – Inside Wirecard’s Investigation discussed by Financial Times Investigative Reporter – Dan McCrum and Themis Founder and CEO – Dickon Johnston and ‘Finding an Entrepreneurial Mindset with VaynerX Chairman and CEO – Gary Vaynerchuk.

One-of-a-kind forums featured during Fintech Abu Dhabi included Blockchain, AI and Risk & Security. Blockchain Abu Dhabi presented in partnership with Circle discussed topics such as the quest to design stability for digital money, digital currencies of Central Banks improving digital asset infrastructure and the overall impact of blockchain and Web3 on the financial industry. AI Abu Dhabi was conducted in collaboration with Mastercard while Risk 4.0 was conducted in association with the Executive Council for Anti-Money Laundering and Counter Terrorism Financing.

During the event, ADGM – in collaboration with its partners, unveiled initiatives to redefine regulatory practices. The Financial Services Regulatory Authority (FSRA) outlined its "Regulation as a Service" strategy through its Digital Lab, aimed at co-creating innovative solutions for the licensing and supervision of firms. Noteworthy collaborations of the FSRA with the National University of Singapore announced aims to develop an AI-powered assessment tool for virtual asset service providers seeking licensing in ADGM.

In its efforts for continuous improvement, the FSRA announced soliciting feedback on a discussion paper related to information technology (IT) risk management to enhance firms’ operational resilience. Furthermore, fostering innovation in Decentralised Finance (DeFi), the FSRA unveiled a collaboration with Coinbase Asset Management and Neoply and also nudged towards a DeFi consultation paper slated for publication in 2024, alongside enhancements to the existing regulatory framework.

Linda Fitz-Alan Registrar and Chief Executive at ADGM Courts said, "In its staggering 7th edition, Fintech Abu Dhabi started as a pioneer, awakening our imagination, guiding the disruption of our norms and making innovation our constant. This is no longer an annual event; this is a pivotal marker to test the temperature and tap into the thoughts of global leaders in financial technology.  The insightful discussions at Fintech Abu Dhabi do not just shape the future of the fintech landscape, but also create its landscape while opening our minds to the endless possibilities for the future of the financial sector."

Furthermore, major announcements by global companies such as GQG Partners (GQG) an independent asset management firm with more than USD 100 billion in AUM and Offset8, a proprietary asset management firm specialising in the global verified carbon credits (VCC) market announced receiving an In-Principle Approval (IPA) from the Financial Services Regulatory Authority (FSRA) of the ADGM. IOTA, the open public goods infrastructure ushering in digital asset innovation, announced its registration as the first company to be registered under the DLT Foundations Regulations of ADGM.

MEVCA and New York and Singapore headquartered-GPCA announced a partnership that will see GPCA establish a permanent presence in the Middle East, with the support of MEVCA.

The Global Financial Regulators Summit, a closed-door gathering of key global financial regulatory leaders was conducted parallel to Fintech Abu Dhabi and discussed the role regulators play in shaping the sustainable finance landscape of the future. The outcomes of the summit will be announced tomorrow during the R.A.C.E (Regulation, Awareness, Collaboration & Ecosystem) Sustainability Summit.

Source : 7th Edition of Fintech Abu Dhabi Explores Synergy Between Finance and Technology

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

MELBOURNE, Australia, Nov. 30, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE study (ClinicalTrials.gov ID NCT04758780) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain (France), will deliver top-line results as a poster presentation at 5pm CT on Wednesday December 6.

The primary objective of the OPALESCENCE study was to evaluate how CAIX-targeted imaging with PET can be utilised for the diagnosis and staging of TNBC and to develop a deeper understanding of CAIX as a potential therapeutic target in this patient population with a significant unmet medical need. 

SABCS is the largest and most prestigious scientific gathering on breast cancer research worldwide. Visit http://www.sabcs.org/ for more information on the congress.

About the Institut de Cancérologie de l’Ouest (ICO)

ICO is a 1,400 professional strong not-for-profit center fighting against cancer. It welcomes close to 48,000 patients per year, and conducts the mission and service of a public hospital. Strengthened by its 4 missions – Prevention, Care, Research and Teaching – ICO offers broad, state-of-the-art expertise that is exclusively dedicated to cancerology. 

Advanced medicine at the service of patients: specialising in oncology, ICO professionals provide patients with personalised, innovative and multidisciplinary care at every stage of their treatment. From rapid diagnosis to surgery, chemotherapy and radiotherapy, care also extends to supportive care, which is highly developed at ICO.

The integration of care, research and innovation is integral to ICO. Research activities, which are a specific mission at ICO, are undertaken from concept all the way through to clinical trials. Research is conducted in all disciplines of cancerology: medical oncology, radiotherapy, surgery, anaesthesia, nuclear medicine, medical imagery, support care, and human sciences. Patients who are cared for at ICO receive privileged access to cutting edge clinical trials in cancerology. The mission of the Innovation Unit is to support innovation in oncology by assisting both internal and external project leaders from the initial idea to the operational implementation of the innovation. Through its teaching mission and academic expertise, ICO contributes to the training of tomorrow’s cancer professionals. For more information contact: [email protected]

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn.

TLX250-CDx has not received a marketing authorisation in any jurisdiction. Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA),[1] by the Australian Therapeutic Goods Administration (TGA),[2] and by Health Canada.[3]

Telix’s SENSEI® ultra-miniaturised robotic gamma probe is registered as a Class 1 device with the FDA, and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area for intra-operative detection of sentinel lymph nodes.[4]

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: [email protected]

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments.  Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.

©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

[1] Telix ASX disclosure 20 December 2021.

[2] Telix ASX disclosure 2 November 2021.

[3] Telix ASX disclosure 14 October 2022.

[4] Lightpoint Medical media release 20 January 2021.

Source : Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Students learned about solving problems through chemistry at company’s Global Innovation Center

THE WOODLANDS, Texas, Nov. 30, 2023 /PRNewswire/ — SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, welcomed approximately 30 students enrolled in the STEM program at Sheldon Independent School District in Houston, Texas to the company’s Global Innovation Center. The event was held to give students firsthand exposure to the world of chemistry and problem-solving through scientific exploration.

The visit showcased SI Group’s commitment to promoting STEM education and inspiring the next generation of scientists. The students engaged in a day filled with interactive sessions and practical demonstrations that highlighted the impact of chemistry in applications such as safer can coatings, asphaltene dispersion in crude oil production and performance enhancement of car tires. The visit included a guided tour of SI Group’s state-of-the-art research facility including the analytical and application development laboratories.

The unique opportunity to interact with SI Group’s team of experienced scientists gave the students valuable insights into the diverse facets of the chemical industry. Furthermore, SI Group’s scientists participated in a discussion with the students about choosing a career in STEM and job opportunities once joining the workforce.

"Taking our STEM Academy to SI Group was eye-opening for the students. They were able to interact with STEM professionals and see the innovative work in the laboratories that produces many of the items we use every day," said Becky Zalesnik, Executive Director of Innovative Programs at Sheldon ISD. "Events like these help students make life-changing career decisions. The partnership between our school and industry partners such as SI Group provides much more than a lesson, we are building the future workforce together."

"We are thrilled to have hosted these bright young minds from Sheldon ISD as part of our ongoing commitment to STEM education," said Narsi Devanathan, Vice President – Research & Development at SI Group. "By engaging with them in a real-world setting, we hope to inspire a passion for science and to ignite their curiosity about the possibilities within the field of chemistry."

SI Group looks forward to continuing its collaboration with local schools and educational institutions to promote STEM education and develop the next generation of innovators.

About SI Group

SI Group is a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates. SI Group solutions are essential to enhancing the quality and performance of countless industrial and consumer goods within the plastics, rubber & adhesives, fuels & lubricants, oilfield, and pharmaceutical industries. SI Group’s global manufacturing footprint includes 20 facilities on three continents, serving customers in 80 countries with approximately 2,000 employees worldwide. In 2021, SI Group received a gold award for corporate social responsibility by EcoVadis and is ranked among the top five percent of more than 50,000 worldwide companies. SI Group innovates and drives change to create value with a passion for safety, chemistry, sustainability, and extraordinary results. Learn more at www.siigroup.com.

Media Contact: Joseph Grande 
ph: + 1.413.684.2463
[email protected]

Source : SI Group Inspires Future Scientists through Event with Sheldon ISD

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network